PLUR

Pluri Inc

2.11

Jul 02 • 04:00PM ET +0.02 (0.96%)

Healthcare Biotechnology Israel Nano NASD

Peers: ALLR BCTX CLRB JSPR LGVN MRKR NXTC PTN TPST VTGN

Scroll to Statements

Index	-
Market Cap	22.77M
Enterprise Value	52.45M
Income	-25.54M
Sales	1.08M
Book/sh	-1.78
Cash/sh	0.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	127
IPO	Apr 16, 2003

P/E	-
Forward P/E	-
PEG	-
P/S	21.08
P/B	-
P/C	2.38
P/FCF	-
EV/EBITDA	-
EV/Sales	48.56
Quick Ratio	0.33
Current Ratio	0.33
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-2.87
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	29.68% 22.58%
Sales past 3/5Y	78.73% 125.33%
EPS Y/Y TTM	20.37%
Sales Y/Y TTM	4.35%
EPS Q/Q	41.08%
Sales Q/Q	-60.89%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	42.59%
Insider Trans	0.00%
Inst Own	12.67%
Inst Trans	0.09%
ROA	-80.48%
ROE	-
ROIC	-
Gross Margin	-3.15%
Oper. Margin	-2410.84%
Profit Margin	-2366.91%
SMA20	-3.93%
SMA50	-21.60%
SMA200	-37.85%
Trades

Shs Outstand	10.43M
Shs Float	6.19M
Short Float	0.27%
Short Ratio	1.54
Short Interest	0.02M
52W High	5.96 -64.60%
52W Low	1.99 6.03%
Volatility	4.56% 5.18%
ATR (14)	0.14
RSI (14)	38.15
Beta	0.65
Rel Volume	0.20
Avg Volume	10.98K
Volume	2,206

Perf Week	-2.31%
Perf Month	-10.78%
Perf Quarter	-37.01%
Perf Half Y	-28.23%
Perf YTD	-29.43%
Perf Year	-60.85%
Perf 3Y	-67.11%
Perf 5Y	-93.34%
Perf 10Y	-98.05%
Recom	1.00
Target Price	12.00
Prev Close	2.09
Price	2.11
Change	0.96%

Jun-02-26 07:30AM	Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing (GlobeNewswire)
May-14-26 06:12PM	Pluri: Fiscal Q3 Earnings Snapshot (Associated Press)
Mar-31-26 07:00AM	Plurilock Announces Payment of Debenture Interest (TMX Newsfile)
Mar-26-26 08:30AM	Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement (GlobeNewswire)
Mar-24-26 07:00AM	Plurilock Announces $445,000 Security Software Renewal with U.S. Department of Defense Agency (TMX Newsfile)
07:00AM	Loading…
Mar-17-26 07:00AM	Plurilock Announces Spring 2026 Cyber Defense Conference and Event Attendance (TMX Newsfile)
Feb-18-26 08:00AM	Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent (GlobeNewswire)
Feb-12-26 05:12PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -5.08%
Feb-09-26 10:30AM	Pluri showcases cell expansion platform as Resbiomed program advances (Proactive) +10.37%
Jan-22-26 09:15AM	Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials (GlobeNewswire) +9.30%
Dec-22-25 07:00AM	Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved (GlobeNewswire)
Dec-09-25 08:30AM	Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment (GlobeNewswire) +9.90%
Nov-13-25 08:00AM	Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year (GlobeNewswire) -6.07%
Nov-12-25 04:55PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +7.49%
Nov-11-25 08:00AM	Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare (GlobeNewswire) +6.15%
08:00AM	Loading…
Nov-10-25 08:00AM	Leading Global Players Back and Fund Pluri's Cell-Based Food and Agriculture Collaborations (GlobeNewswire) +18.54%
Oct-24-25 08:07AM	Pluri Subsidiary Coffeesai Partners with Mexico's INCAFECH to Advance Cell-Based Coffee Manufacturing (Insider Monkey)
Oct-08-25 09:00AM	Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico (GlobeNewswire) -5.12%
Aug-14-25 04:30PM	Plurilock Announces Dates for Second Quarter 2025 Financial Results (Newsfile)
May-15-25 07:00AM	Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion (GlobeNewswire)
May-13-25 04:43PM	Pluri: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -9.32%
Apr-28-25 08:00AM	Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. (GlobeNewswire) -13.67%
Apr-11-25 10:37AM	Pluris immune cell expansion technologies gain patents (Pharmaceutical Technology)
Apr-10-25 08:30AM	Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel (GlobeNewswire) -6.03%
Mar-05-25 07:00AM	Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness (GlobeNewswire) +5.86%
Feb-19-25 09:01AM	Ever After Foods and Buhler Collaborate to Scale Cultivated Meat Production and Distribution (GlobeNewswire)
09:01AM	Ever After Foods and B hler Collaborate to Scale Cultivated Meat Production and Distribution (GlobeNewswire)
Feb-11-25 05:37PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-04-25 07:00AM	Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million (GlobeNewswire)
Jan-24-25 09:25AM	Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market (TipRanks)
07:15AM	Loading…
Jan-23-25 07:15AM	Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition (GlobeNewswire) +6.40%
Dec-19-24 08:00AM	Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease (GlobeNewswire)
Dec-09-24 09:00AM	Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
Nov-25-24 08:30AM	Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns (GlobeNewswire) +7.55%
Nov-12-24 05:52PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +8.43% +9.22%
01:00PM	Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Nov-11-24 06:00AM	BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing (PR Newswire) +11.92%
Oct-28-24 07:00AM	Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority (GlobeNewswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Jul-18-24 02:30AM	Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates (GlobeNewswire)
Jul-08-24 07:00AM	Pluri Announces 1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply (GlobeNewswire)
Jun-18-24 06:30AM	Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges (GlobeNewswire)
Jun-06-24 06:45AM	U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract (GlobeNewswire)
May-20-24 07:00AM	Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale (GlobeNewswire)
May-02-24 07:00AM	Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment (GlobeNewswire) +5.03%
Apr-08-24 07:00AM	Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method (GlobeNewswire)
Apr-03-24 02:52PM	PLUR Stock Earnings: Pluri Reported Results for Q4 2023 (InvestorPlace) -8.70%
Mar-28-24 07:15AM	Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences (GlobeNewswire) -8.39%
Mar-27-24 07:00AM	Pluri Inc. Announces 1-for-8 Reverse Share Split (GlobeNewswire) -13.75%
Mar-21-24 07:00AM	Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report (GlobeNewswire)
Mar-19-24 04:00AM	Engage with Pluri's Talent: Exciting Conference Appearances Ahead (GlobeNewswire)
Mar-14-24 07:00AM	Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing (GlobeNewswire)
Mar-11-24 07:00AM	Pluri Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation (GlobeNewswire)
Mar-06-24 07:00AM	Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board (GlobeNewswire) +13.77%
Feb-28-24 07:00AM	Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals (GlobeNewswire)
Feb-12-24 05:20PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.49%
Jan-23-24 02:00AM	Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis (GlobeNewswire) +15.81%
Jan-08-24 07:00AM	Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization (GlobeNewswire) -6.79%
Dec-21-23 07:00AM	Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction (GlobeNewswire)
Nov-13-23 07:29PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.99%
Aug-16-23 07:00AM	Pluris PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation (GlobeNewswire)
Jul-13-23 02:00AM	Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors (GlobeNewswire) +5.54%
Jul-12-23 11:17AM	Deutsche Bank Predicts up to 160% Rally for These 3 Stocks Heres Why They Have Solid Upside (TipRanks) -5.25%
Jul-11-23 02:00AM	U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome (GlobeNewswire) +8.91%
Apr-27-23 07:00AM	Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products (GlobeNewswire)
Mar-13-23 08:00AM	Israels Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity (GlobeNewswire)
Dec-22-22 07:00AM	Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept (GlobeNewswire)
Dec-15-22 04:05PM	Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.30%
Nov-10-22 07:00AM	Pluri wins BioTech Breakthrough Cell Innovation of the Year Award (GlobeNewswire) +8.10%
Oct-31-22 08:00AM	Pluri to Present and Participate in Upcoming Conferences (GlobeNewswire)
Sep-29-22 07:00AM	Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates (GlobeNewswire)
Sep-06-22 07:00AM	7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluris PLX-PAD Cells for Osteoarthritis Treatment (GlobeNewswire)
Apr-07-22 07:00AM	Plurilock's Aurora Systems Receives US$224,000 Purchase Order from the U.S. Library of Congress (Newsfile)
Apr-01-22 07:00AM	Plurilock Names Garr Stephenson Jr. as Chief Revenue Officer (Newsfile)
Mar-31-22 07:00AM	Plurilock's Aurora Systems Receives US$1.5 Million Purchase Order from the U.S. Department of Defense (Newsfile)
Mar-28-22 07:00AM	Plurilock Submits Non-Provisional U.S. Patent Application for Multi-Device Identity Confirmation Technology (Newsfile)
Mar-23-22 07:00AM	Plurilock's Aurora Systems Receives US$1.85 Million Purchase Order from the U.S. Department of the Navy (Newsfile)
Mar-17-22 07:00AM	Plurilock Adds Brandon Swafford to Advisory Board (Newsfile)

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

PresidentMr. Yaacov Yanay

CFO & TreasurerMs. Liat Zalts

Vice President of Operations & ManufacturingMr. Ori Shalem

Chief Technology OfficerMr. Lior Raviv

Chief Scientific OfficerDr. Arthur Machlenkin Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manieu Alexandre Weinstein	Director	Oct 29 '25	Option Exercise	0.00	1,002,169	100	1,933,415	Nov 20 11:35 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

PLUR

Pluri Inc

Upgrade your Finviz experience